Articles with the keyword: 
Economics school study finds no link between adult testosterone regimens and financial risk-taking
Darkfrog submitted, created time 11 months 1 week (www.nature.com)
For a while now, researchers have noticed that men and women behave differently in financial situations. In particular, men appear to be much more aggressive in things like day trading, while women tend to take a more sedate tack. To see if the quintessential male hormone, testosterone, was responsible, researchers measured the levels of testosterone in the saliva of male securities traders and found a positive correlation between higher testosterone levels and more risk-taking 
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline)
piggy submitted, created time 11 months 3 weeks (www.bizjournals.com)
Wyeth Pharmaceuticals, a division of Wyeth announced today that the U.S. Food and Drug Administration (FDA) approved TYGACIL(R) (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. TYGACIL was first approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) caused by susceptible strains of indicated pathogens in adults.
US FDA staff question risks with Bayer-J&J drug
piggy submitted, created time 1 year 1 day (money.cnn.com)
Food and Drug Administration staff expressed concern over bleeding and other risks with Bayer AG's and Johnson & Johnson's blood-thinning drug Xarelto in documents released Tuesday, sending the companies' shares lower.
"The evidence that administration of rivaroxaban (Xarelto) could lead to bleeding events in significantly more patients relative to enoxaparin amplifies this safety concern for rivaroxaban," the staff wrote in one review.
Health Insurance Essential for Health and Well-being
sea-maid submitted, created time 1 year 3 weeks (www.sciencedaily.com)
The evidence shows more clearly than ever that having health insurance is essential for people's health and well-being, and safety-net services are not enough to prevent avoidable illness, worse health outcomes, and premature death, says a new report from the Institute of Medicine. Moreover, new research suggests that when local rates of uninsurance are relatively high, even people with insurance are more likely to have difficulty obtaining needed care and to be less satisfied with the care they receive.
Are You a Moneymaker? Look at Your Hands
sea-maid submitted, created time 1 year 2 months (sciencenow.sciencemag.org)
Could the reason for the world's economic woes all come down to finger length? Although certainly an oversimplification of our current troubles, scientists have shown that financial traders who lose the biggest bucks are more likely to have shorter ring fingers than index fingers.
HIV testing on the cheap! ...but no one's interested.
Darkfrog submitted, created time 1 year 3 months (www.nature.com)
The standard HIV test, such as a patient might receive in a hospital in New York or Paris, is generally too expensive for AIDS prevention organizations in Africa. However, new developments that could make HIV testing more feasible are not garnering enough interest from private investors.
These tests are not limited to determining who is infected and who isn't. For example, CD4 tests, which measure HIV-indicative changes in the patient's cell receptors, are used to tell how far the disease has progressed, which can help doctors give their patients the most effective drug regimens
J&J to buy breast implant firm Mentor for $1.1 bln
piggy submitted, created time 1 year 3 months (www.reuters.com)
Johnson & Johnson will buy breast implant maker Mentor Corp for $1.07 billion as the diversified healthcare giant pushes into the market for cosmetic medical procedures.
J&J's tender offer for Mentor, announced on Monday, is $31 per share, a 92 percent premium to Mentor's closing price on Friday, although the shares traded above $40 at the start of 2008.
The acquisition underscores the interest in the market for plastic surgery and other aesthetic procedures even at a time when the rocky global economy may limit consumers' ability to pursue such options.
Johnson & Johnson to acquire Israel's Omrix for $465 million
piggy submitted, created time 1 year 3 months (www.reuters.com)
Johnson & Johnson Inc will acquire Israel's Omrix Biopharmaceuticals Inc for $27 a share, or a total of $465 million, the Globes financial news website said on Monday.
Omrix, which makes biosurgical sealants for the prevention of bleeding, or homeostasis, in surgery, is a partner of Johnson & Johnson unit Ethicon.
Ethicon has exclusive sales and marketing rights to Omrix's biosurgical products in the United States and the European Union.
A team from Ethicon was in Israel at the end of last week reviewing the company, the Globes report said
Industry shifts focus to immunology and cancer
sea-maid submitted, created time 1 year 4 months (www.nature.com)
Economic factors, including competition from generic drugs, is hitting even the big pharmaceutical companies hard, reports Nature. In 2010, Pfizer's Lipitor enters the public domain. For these reasons, the larger companies are narrowing the focus of their research, hitting fewer diseases. They're also working on fewer primary care drugs and more drugs that would be prescribed by specialists, such as cancer drugs.
"When Wyeth Pharmaceuticals announced last week that it would cut some of its research and development (R&D) programs in women's health, the decision seemed counterintuitive
Economics: In defense of Smith--it's not like he didn't warn us
Darkfrog submitted, created time 1 year 4 months (www.nature.com)
I really liked reading this article. Ostensibly, it's about how all the pro economists know that there are flaws in the traditional economic models, but no one talks about them to intro students or in the media. Even undergraduate economics students are taught the traditional models in their basic classes, but they graduate and go into financial professions without anyone ever mentioning the points at which these models fail to work.
The public is left to assume that the models are wrong and that the economists must have some spooky ulterior motive
Savient shares fall over gout drug safety concerns
sea-maid submitted, created time 1 year 4 months (biz.yahoo.com)
Shares of Savient Pharmaceuticals plunged Monday as Wall Street urged caution over the safety profile of the drug developer's candidate for gout treatment Puricase.
The stock plunged $8.51, or 73.5 percent, to $3.07. Earlier in the session, shares fell to $2.80, their lowest point in more than three years.
On Monday, Savient reported more late-stage study data on Puricase, reinforcing its effectiveness in prior results. If approved, the drug would be administered intravenously, with the goal of removing uric acid from the blood
sea-maid submitted, created time 1 year 4 months (www.fiercebiotech.com)
VioQuest Pharmaceuticalstoday provided a strategic alternatives review and operations update.
sea-maid submitted, created time 1 year 4 months (www.fiercebiotech.com)
Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that it has entered into a letter of intent for a business combination with Medigen Biotechnology Corp. ("Medigen"), a biotech company traded over the bulletin board in Taiwan. In connection with the transaction, Pacgen would acquire all of the issued and outstanding shares of Medigen by way of share purchase or through such other transaction structure as may be determined by the mutual agreement of Medigen and Pacgen
BioTie Therapies Inc. to Acquire Neurology and Immunology Focused Pharmaceutical Company Elbion GmbH
sea-maid submitted, created time 1 year 4 months (www.fiercebiotech.com)
BioTie Therapies has today entered into an agreement to acquire the German pharmaceutical company elbion GmbH. The combination of the two businesses will take place by a share exchange and create a leading European company in the field of discovery and development of therapeutics for central nervous system (addiction, psychotic disorders) and inflammatory diseases (e.g. rheumatoid arthritis, psoriasis and inflammatory diseseas of the respiratory system). elbion GmbH will become a wholly-owned subsidiary of BioTie.
Ark floats gene therapy's boat, for now
sea-maid submitted, created time 1 year 4 months (www.nature.com)
In August, gene therapy's turbulent ride through the clinical rapids took a new twist as Ark Therapeutics released positive top-line results from a phase 3 trial of its adenoviral gene therapy Cerepro (sitimagene ceradenovec) for malignant brain tumors. Although the news boosted the London-based firm's shares, the course to market authorization and registration remains strewn with uncertainty—as Introgen, of Austin, Texas, found, to its cost, when the U.S
abuse@discover8.com
kavin
angelfish
jane2007
Sue Wu
DanyC
GenScript plasmid DNA preparation services offer endotoxin FREE and predominantly supercoiling plasmid DNA from 100 ug to 1000 mg start from $50.
www.genscript.com
Monoclonal Antibody Services
GenScript's custom monoclonal antibody service guarantees two ELISA positive clones with any antigen via High hybridoma technology & experienced professionals.
www.genscript.com